Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nancy U Lin

Showing results (211-220 of 330) with videos related to

Pageof 33
Sort By:
NPJ Breast Cancer|May 16, 2018
Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancerDaniel G Stover, Carlos R Gil Del Alcazar, Jane Brock, et al.
Pharmacology & Therapeutics|October 10, 2025
Treatment strategies for leptomeningeal disease in patients with breast cancerLennard Spanehl, Thomas Grinda, Rishab Ramapriyan, et al.
NPJ Breast Cancer|June 2, 2023
Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancerAna C Garrido-Castro, Meredith M Regan, Samuel M Niman, et al.
JCO Precision Oncology|January 20, 2022
Clinical Pan-Cancer Assessment of Mismatch Repair Deficiency Using Tumor-Only, Targeted Next-Generation SequencingAdem Albayrak, Ana C Garrido-Castro, Marios Giannakis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2014
Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guidelineNaren Ramakrishna, Sarah Temin, Sarat Chandarlapaty, et al.
The Lancet. Oncology|March 9, 2017
iRECIST: guidelines for response criteria for use in trials testing immunotherapeuticsLesley Seymour, Jan Bogaerts, Andrea Perrone, et al.
Breast Cancer Research and Treatment|January 23, 2022
Perceptions of patients and medical oncologists toward biospecimen donation in the setting of abnormal breast imaging findingsDavinia S Seah, Nabihah Tayob, Jose Pablo Leone, et al.
Nature Genetics|December 12, 2018
Acquired HER2 mutations in ER<sup>+</sup> metastatic breast cancer confer resistance to estrogen receptor-directed therapiesUtthara Nayar, Ofir Cohen, Christian Kapstad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2014
Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guidelineSharon H Giordano, Sarah Temin, Jeffrey J Kirshner, et al.
Breast Cancer Research and Treatment|April 7, 2026
The LIFT UP study: feasibility of systematically identifying and addressing resource needs in those with metastatic breast cancerTemidayo A Fadelu, Ashley Odai-Afotey, Alyssa Martin, et al.
Pageof 33

Showing results (211-220 of 330) with videos related to

Sort By:
Pageof 33
NPJ Breast Cancer|May 16, 2018
Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancerDaniel G Stover, Carlos R Gil Del Alcazar, Jane Brock, et al.
Pharmacology & Therapeutics|October 10, 2025
Treatment strategies for leptomeningeal disease in patients with breast cancerLennard Spanehl, Thomas Grinda, Rishab Ramapriyan, et al.
NPJ Breast Cancer|June 2, 2023
Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancerAna C Garrido-Castro, Meredith M Regan, Samuel M Niman, et al.
JCO Precision Oncology|January 20, 2022
Clinical Pan-Cancer Assessment of Mismatch Repair Deficiency Using Tumor-Only, Targeted Next-Generation SequencingAdem Albayrak, Ana C Garrido-Castro, Marios Giannakis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2014
Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guidelineNaren Ramakrishna, Sarah Temin, Sarat Chandarlapaty, et al.
The Lancet. Oncology|March 9, 2017
iRECIST: guidelines for response criteria for use in trials testing immunotherapeuticsLesley Seymour, Jan Bogaerts, Andrea Perrone, et al.
Breast Cancer Research and Treatment|January 23, 2022
Perceptions of patients and medical oncologists toward biospecimen donation in the setting of abnormal breast imaging findingsDavinia S Seah, Nabihah Tayob, Jose Pablo Leone, et al.
Nature Genetics|December 12, 2018
Acquired HER2 mutations in ER<sup>+</sup> metastatic breast cancer confer resistance to estrogen receptor-directed therapiesUtthara Nayar, Ofir Cohen, Christian Kapstad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2014
Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guidelineSharon H Giordano, Sarah Temin, Jeffrey J Kirshner, et al.
Breast Cancer Research and Treatment|April 7, 2026
The LIFT UP study: feasibility of systematically identifying and addressing resource needs in those with metastatic breast cancerTemidayo A Fadelu, Ashley Odai-Afotey, Alyssa Martin, et al.
Pageof 33